 |
 |
Wasn’t this information provided in your abstract?
Dr
Cecilia
Macleod
FRSC FGS CCHEM CSCI
Director
WYG
100 St John Street, London, EC1M 4EH
Tel: +44
207 250 7752
Fax: +44
207 250 7501
Mob: +44
7881 914 370
www.wyg.com
••••••••••••••••••••••••••••••••••••••••••••••••••••••
|
WYG Environment Planning Transport Limited. Registered in England number: 3050297. Registered Office: Arndale Court, Otley Road, Headingley, Leeds, West Yorkshire
LS6 2UJ VAT No: 431-0326-08
|
From: Contaminated Land Management Discussion List [mailto:[log in to unmask]]
On Behalf Of Beriro, Darren J.
Sent: 11 September 2015 14:11
To: [log in to unmask]
Subject: Organic Human Bioaccessibility Survey
Dear Group,
I am speaking at the gasworks MGP 2015 symposium in Ghent later this year (http://mgpsymposium.com/) and in support of
this I would like to conduct a survey to assess the application of organic bioaccessibility testing to human health risk assessment in the UK. If you have any involvement in this aspect of risk-based land management I would be very grateful for your participation.
Please could you respond to me directly via [log in to unmask] and I will collate the responses and summarise the results to the group. I have adopted the word 'use' in the questions but this refers to implementation,
commissioning, reviewing and/or using the test / test results.
The survey questions are as follows:
1.
Which method(s) of bioaccessibility testing have you used?
2.
Which pathway did you apply the test to?
3.
At how many sites have you used the test?
4.
What context were the test results used e.g. derivation of site specific risk assessment criteria prior to remediation, derivation remediation targets?
5.
Which substances were tested e.g. BaP, PCB-118?
6.
Would you be willing to share the results of the test with me for collation i.e. number of samples, averaging area, % bioaccessible fraction for each
sample (anonymity of sample location assumed)?
7.
What difference did the results make to the decision making process e.g. increased site specific assessment criteria and therefore reduced remediation?
8.
What other lines-of-evidence did you use to support the test results?
When responding please can you state your name, affiliation, position and whether you would mind being contacted to follow up on any of your answers. If you
are responding as a lab then I understand that some of the questions might not apply. Thank you very much in advance for your assistance.
Best wishes,
Darren
-------------------------------------
-------------------------------------
Medical Geology
Environmental Modelling
British Geological Survey
Keyworth
Nottingham
NG12 5GG
Direct dial: 0115 936 3479
Swtichboard: 0115 936 3100
-------------------------------------
-------------------------------------
________________________________
This message (and any attachments) is for the recipient only. NERC is subject to the Freedom of Information Act 2000 and the contents of this email and any reply you make may be disclosed by NERC unless it is exempt from release under the
Act. Any material supplied to NERC may be stored in an electronic records management system.
________________________________
